Uptravi IV Offers Important Option for Patients, Exec Says

Uptravi IV Offers Important Option for Patients, Exec Says

302781

Uptravi IV Offers Important Option for Patients, Exec Says

In late July, the U.S. Food and Drug Administration (FDA) approved a new formulation of Janssen‘s Uptravi (selexipag) for use by people with pulmonary arterial hypertension (PAH). Uptravi already was available as an oral tablet. The new formulation is intravenous (IV) — meaning it is administered by an infusion directly into the bloodstream. It is intended to prevent treatment interruptions in patients who are temporarily unable to take oral medications. “Previously, patients who were unable to take…

You must be logged in to read/download the full post.